Therapy Areas: Central Nervous System
Alkermes plc names new director
27 May 2022 -

Alkermes plc (Nasdaq: ALKS), an Ireland-based fully-integrated, global biopharmaceutical company, announced on Thursday that it has named Christopher I Wright, MD Phd as its new director effective 24 May 2022.

Dr Wright has around three decades of drug development and clinical expertise in diseases of the central nervous system. Presently, he serves as chief medical officer at AavantiBio, Inc. and earlier served in senior medical and clinical roles at Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Axcella Health Inc., and Vertex Pharmaceuticals Incorporated. He has over 20 years of experience as both a practicing, board-certified neurologist at Brigham and Women's Hospital in Boston and as an associate professor of Neurology at Harvard Medical School.

Dr Wright said, 'I'm delighted to join Alkermes' board as the company seeks to develop innovative medicines and focus on real-world challenges faced by people living with complex and serious neuropsychiatric diseases. Neuroscience remains an untapped frontier in medicine and I look forward to working with the board and Alkermes' management team as they focus on advancing new medicines to help address the significant unmet needs that remain.'



Related Headlines